How many UTIs constitute a recurrent UTI?

A recurrent UTI is medically defined as two or more confirmed urinary tract infections within a 6-month period, or three or more infections within a 12-month period.

Why do I keep getting UTIs even after taking antibiotics?

Recurrent UTIs despite antibiotic treatment can occur due to antibiotic resistance, reinfection, incomplete eradication, or underlying anatomical or hormonal factors. A specialist evaluation with urine culture is essential.

Can recurrent UTIs be prevented?

Yes - recurrent UTIs can often be significantly reduced or eliminated with the right prevention strategy including low-dose antibiotic prophylaxis, vaginal estrogen therapy for postmenopausal women, behavioral modifications, and evidence-based supplements.

Do I need to see an infectious disease specialist or can my primary care doctor treat recurrent UTIs?

While primary care physicians can treat individual UTI episodes, recurrent UTIs benefit significantly from infectious disease specialist evaluation with specialized training in antibiotic resistance patterns and evidence-based prevention strategies.

Is long-term antibiotic use for UTI prevention safe?

Low-dose antibiotic prophylaxis for recurrent UTI prevention has a well-established safety record when properly managed. Specialists carefully select the safest antibiotic at the lowest effective dose and regularly reassess.

Does Atlas IDP accept insurance for recurrent UTI treatment?

Yes, Atlas Infectious Disease Practice accepts most major insurance plans. Call (561) 995-6971 to verify your specific insurance coverage before your appointment.

Outbreaks News Archives

Login / Signup

Early Release – Borrelia afzelii Hepatitis in Patient Treated with Venetoclax and Obinutuzumab, Switzerland – Volume 31, Number 11—November 2025 – Emerging Infectious Diseases journal

Early Release – Extensively Drug-Resistant Tuberculosis with Conflicting Resistance Testing Results, Lesotho – Volume 31, Number 11—November 2025 – Emerging Infectious Diseases journal

Early Release – Spiroplasma ixodetis in Ticks Removed from Humans, Sweden and Åland Islands, Finland – Volume 31, Number 11—November 2025 – Emerging Infectious Diseases journal

Communicable disease threats report, 22 – 28 November 2025, week 48

Early Release – Isolation and Characterization of Rickettsia finnyi, Novel Pathogenic Spotted Fever Group Rickettsia in Dogs, United States – Volume 31, Number 11—November 2025 – Emerging Infectious Diseases journal

Early Release – Community-Driven, Text Message–Based COVID-19 Surveillance System, Los Angeles County, California, USA, 2020–2024 – Volume 31, Number 11—November 2025 – Emerging Infectious Diseases journal

Early Release – Cladophialophora carrionii [kladˊ-ō-fī-əl-ō-for-ə karˊ-ē-ō-nē-ī] – Volume 31, Number 11—November 2025 – Emerging Infectious Diseases journal

Early Release – Two Autochthonous Cases of Anaplasmosis, Washington, USA, 2022–2023 – Volume 31, Number 11—November 2025 – Emerging Infectious Diseases journal

Early Release – Shifting Dynamics of Dengue Virus Serotype 2 and Emergence of Cosmopolitan Genotype, Costa Rica, 2024 – Volume 31, Number 11—November 2025 – Emerging Infectious Diseases journal

Early Release – Two Independent Acquisitions of Multidrug Resistance Gene lsaC in Streptococcus pneumoniae Serotype 20 Multilocus Sequence Type 1257 – Volume 31, Number 11—November 2025 – Emerging Infectious Diseases journal

Schedule an Appointment

Quick Links

Patient Forms

Contact Us